Clinical trial
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or…
NCT00059865 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00059865 |
|---|---|
| Title | Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer |
| Official title | Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, pemetrexed disodium |
| Enrollment | 68 |
| Start date | Jan 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | May 7, 2003 |
| Last update posted | Dec 7, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: